Since the first case of Ebola virus disease (EVD) in Guinea was reported in 
March 2014 by World Health Organization (WHO), the outbreak has continued 
through the year and the total number of 19,065 patients was reported as the 
confirmed or suspected in the EVD-affected countries. Among the cases, 7,388 
patients were reported death by 19 December. Currently, available therapeutics 
to treat the infected patients or vaccines to prevent people from infection is 
not developed yet while viral diagnostic methods were already developed and 
firmly established in a lot of countries as a first step for the preparedness of 
Ebola outbreak. Some potential therapeutic materials including ZMapp were 
supplied and the treated people got over the EVD. Several candidates of vaccines 
also were investigated their efficacy in animal models by National Institute of 
Health (NIH) and Department of Defense, and they are processing of clinical 
tests in West Africa aiming to finish the development by the 2015. Vaccine and 
therapeutic development is essential to stop the EVD outbreak in West Africa, 
also to protect the world from the risk which can be generated by potential 
spread of Ebola virus.